A study reveals that blood-cell composition explains up to 53 percent of variation in epigenetic age clocks. Learn how immune shifts affect test results.
In October 2026, researchers affiliated with Leiden University Medical Center and the University of Edinburgh published a Genome Medicine study analyzing how blood-cell composition affects DNA-methylation age.
The research concluded that estimated blood-cell composition accounts for up to 53 percent of the variation in methylation-predicted age across six different epigenetic clocks. This indicates that a higher biological age score might partly reflect shifts in immune cell balance rather than a purely cell-intrinsic aging process. These findings highlight a critical distinction for anyone interpreting consumer epigenetic tests.
This study was an observational analysis conducted in humans, utilizing thousands of whole-blood samples from Dutch and Scottish biobanks.
Epigenetic clocks measure changes in DNA methylation over time. Researchers use these chemical patterns to estimate a biological age score for individuals. The analysis examined data from 4,058 whole-blood samples drawn from six Dutch biobanks within the BIOS Consortium. The participants in this cohort were 18 to 87 years old.
Measuring methylation in whole blood means testing a mixture of different cell types. Scientists wanted to know if changes in a clock reading just reflect a changing cellular mixture. To investigate this question, researchers estimated 12 distinct blood-cell fractions using the EpiDISH deconvolution algorithm. This algorithm identified populations including neutrophils alongside naive and memory T-cell and B-cell subsets.
The cellular mixture in human blood changes as we get older. The study report says neutrophils made up 56.8 percent of the average blood-cell profile. Meanwhile, naive CD4 and CD8 T-cell fractions declined with age while memory T-cell fractions increased.
The study evaluated six specific measures of biological age. These included the Hannum, Horvath, Zhang, PhenoAge, GrimAge and DunedinPACE clocks. Across these six measures, estimated blood-cell composition accounted for 44 percent to 53 percent of the variation in methylation-predicted age. The naive-to-memory T-cell balance was reported as the largest single contributor to this variation.
Cell composition also explained 43.5 percent of the variation in chronological age in the analysis. However, the researchers found a very different pattern when looking at age acceleration. Age acceleration represents the mathematical difference between a clock estimate and a person's actual chronological age.
When analyzing age acceleration, cell composition explained at most 21 percent of the variation. The specific immune cells driving this smaller variation also shifted. For second-generation clocks, neutrophils became more prominent while T-cell contributions largely faded. Thus, the pattern depends entirely on which specific clock output is being interpreted.
The study also explored how these immune shifts relate to future health risks. The article reports a separate analysis in 18,859 Generation Scotland participants. This massive secondary cohort tracked 176 incident health outcomes, which notably included all-cause mortality.
After adjustment for multiple testing, cell composition was independently associated with 12 outcomes. Researchers wanted to see if adjusting for cell composition would erase the predictive power of the epigenetic clocks. The adjustment attenuated clock and outcome associations for four of the six clocks by approximately 2 percent to 7 percent overall.
For mortality predictions specifically, the attenuation ranged from 1 percent to 6 percent. This reported analysis suggests that cell composition can substantially influence predicted age variation. However, it does not account for most of the underlying clock and disease association. The clocks still hold predictive value beyond just counting immune cells.
Consumers often purchase biological age tests hoping to measure tissue aging directly. The defensible takeaway is to treat a blood-based epigenetic result as a measurement heavily influenced by the cellular mixture in the sample. It is not a direct reading of how every organ or tissue in the body is aging.
A high age acceleration result may partly reflect neutrophil abundance according to the report. This is particularly true for results generated by second-generation clocks. However, the study does not establish that any single individual's score is entirely explained by cell composition.
Different algorithms also show varying sensitivities to these underlying immune shifts. The article cautions that Horvath and Zhang readings may be less sensitive to immune composition. At the same time, these specific readings are potentially noisier as health predictors.
The statistical approach taken by the researchers reveals the immense complexity of interpreting blood samples. Blood-cell fractions are highly interdependent because they must always sum to exactly 100 percent. The estimated contribution assigned to one specific cell type can change significantly depending on which other fraction is included or omitted in the model.
The researchers utilized principal-component analysis to address this mathematical constraint. The report states that the first principal component closely tracked neutrophils. The second principal component accurately captured the crucial naive-to-memory T-cell balance.
These advanced statistical adjustments allow scientists to isolate the strongest biological signals. Without such corrections, biological age measurements could be skewed by random variations in a single blood draw. Understanding these mathematical variables is crucial for the ongoing development of reliable diagnostic tools.
The researchers resist treating these cellular changes as mere statistical noise. Immune-cell shifts may themselves carry highly relevant health information. For instance, the transition from naive to memory T-cells is a well-documented feature of immune system aging.
Adjusting these shifts away could accidentally remove biologically meaningful signals alongside any confounding factors. If immune aging drives systemic aging, mathematically hiding the immune changes might weaken the overall measurement. The clocks are likely capturing a combination of actual DNA changes and broader immune system deterioration.
This dual nature makes biomarker interpretation both powerful and challenging for health professionals. The exact numerical findings here are supported by the event article rather than independently verified against the journal paper. Therefore, further validation is necessary before applying these models in a clinical setting.
The longevity industry frequently markets supplements and lifestyle changes as proven methods to reverse epigenetic clocks. However, if a clock is highly sensitive to immune cell ratios, a temporary immune response could alter the score. A short-term shift in neutrophils from a mild infection might register as sudden age acceleration.
This is why consumers should avoid panicking over a single high biological age reading. The score represents a snapshot of a highly dynamic biological system. Advancing longevity science requires patience and an understanding of normal physiological fluctuations.
Future diagnostic tools may need to isolate specific cell populations before analyzing DNA methylation. Examining pure samples of a single cell type would eliminate the confounding effect of tissue mixtures. Until then, whole-blood epigenetic tests remain a blunt but useful instrument for observing population-level health trends.
Large-scale biobanks are essential for untangling complex biological patterns in aging. The primary analysis relied on 4,058 samples collected through the Dutch BIOS Consortium. This extensive dataset provided a robust foundation for estimating the 12 blood-cell fractions accurately.
Including participants from 18 to 87 years old allowed researchers to observe immune shifts across a full human lifespan. The distinct decline in naive T-cells is a hallmark of aging that becomes clearer with such broad chronological representation. Large sample sizes also reduce the statistical noise that plagues smaller biomarker studies.
The secondary analysis utilized an even larger dataset from Generation Scotland. Tracking 18,859 participants and 176 incident health outcomes offers an unprecedented look at how epigenetic marks predict disease. The sheer scale of these combined cohorts makes the findings particularly compelling for clinical professionals.
The immune system relies on neutrophils as a primary defense mechanism against infections. In this specific study, the researchers noted that neutrophils made up 56.8 percent of the average blood-cell profile. Because they are so abundant, any fluctuation in their numbers can drastically alter the overall cellular mixture of a blood sample.
When a person experiences inflammation, their body often produces more neutrophils. If a second-generation epigenetic clock heavily weights these cellular changes, it might interpret acute inflammation as rapid age acceleration. This creates a potential blind spot for individuals using these tests to monitor long-term healthspan.
Scientists must separate temporary immune responses from permanent epigenetic damage. While inflammation is intimately connected to the aging process, it is not the only factor determining cellular longevity. Recognizing the overwhelming presence of neutrophils in blood samples helps researchers refine their predictive algorithms.
Understanding the limitations of current biomarkers is a vital step for the scientific community. Consumers investing in biological age tracking must interpret their results with appropriate caution. A single test cannot definitively establish that a new diet or supplement is slowing the aging process.
If an intervention primarily alters circulating neutrophil levels, it will artificially lower some clock scores. This does not necessarily mean the intervention improved overall tissue healthspan. We must differentiate between changing a surrogate marker and actually extending human health.
The findings regarding second-generation clocks are particularly important for future study designs. Because these newer models incorporate clinical biomarkers, they might be more entangled with immune responses. Researchers must account for these variables when designing the next generation of predictive aging algorithms.
Future investigations will need to track these epigenetic shifts longitudinally in isolated cell populations to determine exactly how much of a biological age score reflects true tissue aging versus passing immune fluctuations.
Accurately interpreting epigenetic clock variations requires separating true cellular aging from temporary immune shifts, an analytical process AgeAmaze simplifies for our readers. We resolve the confusion over conflicting longevity studies, ensuring you understand dense scientific papers so you can evaluate emerging interventions without turning early findings into promises. Read the research
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
